Cargando…

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and epithelial integrity. Inhibition of PDE4 is predicted to have diverse effects via the elevation of the level of cyclic aden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Heng, Zuo, Jianping, Tang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199465/ https://www.ncbi.nlm.nih.gov/pubmed/30386231 http://dx.doi.org/10.3389/fphar.2018.01048

Ejemplares similares

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease
por: Sharma, Manju, et al.
Publicado: (2018)

Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases
por: Mokry, Juraj, et al.
Publicado: (2021)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
por: Joskova, Marta, et al.
Publicado: (2020)

The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
por: Ahmad, Nazir, et al.
Publicado: (2022)

Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors
por: Lee, Sang-Yong, et al.
Publicado: (2017)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
por: Bondarev, Andrey D., et al.
Publicado: (2022)

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis
por: Totani, Licia, et al.
Publicado: (2021)

Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion
por: Kim, Hee Kee, et al.
Publicado: (2017)

In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania amazonensis
por: Silva, Dahara Keyse Carvalho, et al.
Publicado: (2020)

Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice
por: Blednov, Yuri A., et al.
Publicado: (2014)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Editorial: Cyclic Nucleotide Phosphodiesterases (PDEs) in Immune Regulation and Inflammation
por: Brocke, Stefan, et al.
Publicado: (2022)

Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice
por: Yanai, Shuichi, et al.
Publicado: (2022)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Phosphodiesterase 4-targeted treatments for autoimmune diseases
por: Kumar, Neal, et al.
Publicado: (2013)

Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases
por: Wittmann, Miriam, et al.
Publicado: (2013)

Natural Phosphodiesterase-4 Inhibitors with Potential Anti-Inflammatory Activities from Millettia dielsiana
por: Le, Vu Thi Thu, et al.
Publicado: (2023)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells
por: Adderley, Shaquria P., et al.
Publicado: (2012)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Efficacy of phosphodiesterase‐4 inhibitors in juvenile Batten disease (CLN3)
por: Aldrich, Amy, et al.
Publicado: (2016)

The Effects of Acute and Chronic Selective Phosphodiesterase 1 Inhibition on Smooth Muscle Cell-Associated Aging Features
por: Golshiri, Keivan, et al.
Publicado: (2022)

Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells
por: Grundy, Seamus, et al.
Publicado: (2016)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Selective Phosphodiesterase 4B Inhibitors: A Review
por: Azam, Mohammed Afzal, et al.
Publicado: (2014)

Prediction and associated factors of non-steroidal anti-inflammatory drugs efficacy in migraine treatment
por: Lu, Zhao-Xuan, et al.
Publicado: (2022)

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice
por: Rieder, Florian, et al.
Publicado: (2013)

Upregulation of Phosphodiesterase 2A Augments T Cell Activation by Changing cGMP/cAMP Cross-Talk
por: Kurelic, Roberta, et al.
Publicado: (2021)

cAMP Catalyzing Phosphodiesterases Control Cholinergic Muscular Activity But Their Inhibition Does Not Enhance 5-HT(4) Receptor-Mediated Facilitation of Cholinergic Contractions in the Murine Gastrointestinal Tract
por: Pauwelyn, Vicky, et al.
Publicado: (2018)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
por: Facchinetti, Fabrizio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8e3ch9mpdl6h9a0j5t7fmrl3o7